Why the study?
Does dual therapy with ACEi and ARB reduce cardiovascular or renal outcomes compared to monotherapy?
Does dual therapy with ACEi and ARB reduce cardiovascular or renal outcomes compared to monotherapy?
Answers are grounded in this paper and cite their sources.
Despite expectations that combining ACEi and ARB would further reduce blood pressure and albuminuria, the ONTARGET trial demonstrated no additional cardiovascular or renal benefit from dual therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Heerspink et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: